Zai Lab Limited (ZLAB) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $21.56: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Zai Lab is a commercial-stage biopharmaceutical company with seven approved products marketed in Greater China, focused on oncology, immunology, neuroscience, and infectious disease. All commercial operations are in mainland China; products are primarily in-licensed from global... Read more
Sell if holding. Engine safety override at $21.56: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicmainland China10-K Item 1A: 'A substantial portion of our operations, and all of our commercial operations, are conducted in mainland China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Unprofitable operations — net margin -38.1%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $21.56: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $20.05. Score 5.1/10, moderate confidence.
Take-profit target: $30.75 (+42.6% upside). Prior stop was $20.05. Stop-loss: $20.05.
Concentration risk — Geographic: mainland China; Quality below floor (2.0 < 4.0).
Zai Lab Limited trades at a P/E of N/A (forward -14.4). TrendMatrix value score: 8.1/10. Verdict: Sell.
14 analysts cover ZLAB with a consensus score of 3.9/5. Average price target: $35.
What does Zai Lab Limited do?Zai Lab is a commercial-stage biopharmaceutical company with seven approved products marketed in Greater China, focused...
Zai Lab is a commercial-stage biopharmaceutical company with seven approved products marketed in Greater China, focused on oncology, immunology, neuroscience, and infectious disease. All commercial operations are in mainland China; products are primarily in-licensed from global biopharmaceutical partners.